A report from the CDC across the US has found that ASD rates in children aged between 4-8 years were higher in 2022 than in ...

MSD and Daiichi Sankyo have announced first subject dosing in the IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan ...

Skyhawk Therapeutics has dosed the first subject in the randomised Phase II/III FALCON-HD trial of the oral small-molecule ...

NHS England chair Penny Dash shared her views on European healthcare during a fireside discussion at HLTH Europe in Amsterdam ...

Oncology clinical trials are complex and costly, making successful setup critical. Challenges include long timelines and ...

Lyell Immunopharma has reported new clinical data from the Phase I/II clinical trial of CAR T-cell product candidate, LYL314.

Ventyx Biosciences has reported encouraging top-line outcomes from its Phase IIa trial of VTX3232 for early-stage Parkinson's ...

Clarametyx Biosciences has received approval from the Independent DMC to progress its Phase Ib/IIa trial of CMTX-101 ...

This space already includes two approved CAR T-cell therapies: Johnson & Johnson/Legend’s Carvykti and Bristol Myers Squibb’s ...

The US FDA has approved Ocugen’s IND amendment to commence a Phase II/III pivotal confirmatory study of OCU410ST.

Astria Therapeutics has reported encouraging initial outcomes from its ongoing ALPHA-SOLAR trial of navenibart for HAE ...

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...